Clinical trials: Methylphenidate
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer
This randomized phase II trial studies how well cognitive behavioral therapy and multimodal therapy works in treating sleep disturbance in patients with cancer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Sleep Disorder
- Trial name
- NCT01628029
- Testing
- Counseling, Methylphenidate Hydrochloride, Phototherapy
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Attention Deficit Disorder With Hyperactivity (ADHD)
The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
The aim of this study was to investigate the effect of treatment of ADHD with methylphenidate on neuroinflammation by examining the levels of Interleukin-6 (IL-6), S100B, Claudin-5 in serum samples of patients who were diagnosed…
- Trial name
- NCT07041333
- Where
- Turkey (Türkiye)
- Volunteers
- 57 people
- Sponsor
- Enes Faruk ALTUNKILIÇ
Attention Deficit Hyperactivity Disorder (ADHD)
The Effect of Methylphenidate Treatment on Oxidative Stress Levels in Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)
The aim of this study is to investigate the effect of methylphenidate treatment on oxidative stress by measuring the levels of Total Oxidant Status (TOS), Total Antioxidant Status (TAS), Oxidative Stress Index (OSI=TOS/TAS)…
- Trial name
- NCT06844812
- Testing
- This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study.
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Attention Deficit Disorder With Hyperactivity
Neuroimaging of the Effects of Concerta in the Treatment of ADHD
A number of brain regions have been down to be altered in both structure and function in patients with ADHD, including prefrontal cortex, anterior cingulate, caudate and cerebellum.
- Trial name
- NCT00778310
- Testing
- methylphenidate-OROS
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
ADHD
Motivated Behavior in Adults With and Without ADHD
To investigate the effects of methylphenidate on motivated behavior in adults with and without ADHD
- Trial name
- MOBE (NCT02630017)
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Attention-Deficit/Hyperactivity Disorder
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over…
- Trial name
- RE-DAX (NCT04507204)
- Testing
- Adhansia XR, Concerta
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Purdue Pharma LP
Attention Deficit/Hyperactivity Disorder
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
The purpose of this study is to assess the long-term safety of Adhansia XR in children and to characterize the pharmacokinetics (PK) in 4 to 5 year-olds.
- Trial name
- NCT04987762
- Testing
- Adhansia XR
- Where
- 15 sites in United States
- Volunteers
- 103 people
- Sponsor
- Purdue Pharma LP
Apathy, Alzheimer's Disease
Apathy in Dementia Methylphenidate Trial 2
Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, multi-center randomized clinical trial sponsored by National Institutes of Aging involving 200 participants with…
- Trial name
- ADMET2 (NCT02346201)
- Testing
- Methylphenidate
- Where
- 10 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Healthy
Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test dexmethylphenidate hydrochloride formulation to an equivalent oral dose of the commercially available dexmethylphenidate…
- Trial name
- NCT00829673
- Testing
- Dexmethylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
Apathy, Diabetes
The Role of Apathy in Glycemic Control
In spite of several new medications and insulins for the control of blood sugars in patients with diabetes, a large number of patients do not have good control.
- Trial name
- NCT00844090
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- US Department of Veterans Affairs
Healthy
Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test dexmethylphenidate hydrochloride formulation to an equivalent oral dose of the commercially available dexmethylphenidate…
- Trial name
- NCT00829712
- Testing
- Dexmethylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
ADHD
The Reinforcing Mechanisms of Smoking in Adult ADHD
Whereas the smoking prevalence rates in the general population are declining, rates among people diagnosed with attention-deficit hyperactivity disorder (ADHD) continue to be elevated.
- Trial name
- NCT00573859
- Testing
- ADHD medication
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Attention Deficit Hyperactivity Disorder
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
This study will assess the frequency of chromosomal abnormalities measured in circulating lymphocytes in treatment-naive children with Attention Deficit Hyperactivity Disorder (ADHD) treated for 3 months with either extended…
- Trial name
- NCT00409708
- Testing
- Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Novartis
Opioid Abuse, Opioid Addiction
The Discriminative Effects of Tramadol in Humans
This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram.
- Conditions
- Opioid Abuse, Opioid Addiction, Stimulant Abuse, Stimulant Addiction
- Trial name
- NCT00499746
- Testing
- tramadol, Hydromorphone, Methylphenidate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning…
- Trial name
- NCT02096952
- Testing
- Methylphenidate extended-release liquid formulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Attention-Deficit Hyperactivity Disorder
An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate the efficacy of JNS001 titrated to daily doses of 18 to 72 mg in adults with attention-deficit hyperactivity disorder (ADHD) relative to placebo.
- Trial name
- NCT01323192
- Testing
- JNS001
- Where
- 30 sites in Japan
- Volunteers
- 284 people
- Sponsor
- Janssen Pharmaceutical K.K.
Breast Cancer, Fatigue
Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients
The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl (Concerta) can help to control fatigue in patients with breast, gastrointestinal, lymphoma, myeloma or lung cancer who are going through…
- Conditions
- Breast Cancer, Fatigue, Gastrointestinal Cancer
- Trial name
- NCT00516269
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Omega-3 Supplementation to ADHD Medication in Children
This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children…
- Trial name
- NCT02204410
- Testing
- Omega-3 Fatty Acid, ADHD Medication
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit/ Hyperactivity Disorder
A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the efficacy of 2 fixed dosages of Prolonged Release (PR) OROS methylphenidate (54 and 72 mg/day) compared with placebo in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00714688
- Testing
- prolonged release (PR) OROS methylphenidate 54 mg, prolonged release (PR) OROS methylphenidate 72 mg
- Where
- 42 sites in Belgium, Denmark and 9 more
- Volunteers
- 279 people
- Sponsor
- Janssen-Cilag International NV